                         SEQUENCE LISTING

<110>  Oregon Health & Science University
       The Government of the United States of America, dba, The 
       Department of Veterans Affairs
       Forte, Michael
       Bourdette, Dennis
       Marracci, Gail
 
<120>  Cyclic Undecapeptides and Derivatives as Multiple Sclerosis 
       Therapies

<130>  899-79630-02

<150>  US 10/975,502
<151>  2007-09-26

<160>  5     

<170>  PatentIn version 3.5

<210>  1
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cyclosporin formula 1


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is N-methyl-(4R)-4-but-2E-en-1-yl-4-methyl-(L)threonine; 
       dihydro-N-methyl-(4R)-4-but-2E-en-1-yl-4-methyl-(L)threonine; or 
       8'-hydroxy-N-methyl-(4R)-4-but-2E-en-1-yl-4-methyl-(L)threonine

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is alpha-aminobutyric acid; Val, Thr, norvaline, or 
       O-methylthreonine

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is sarcosine, (D)-N-methylserine, (D)-N-methylalanine, or 
       (D)-N-methylserine(Oacetyl)

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is N-methylleucine, gamma-hydroxy-N-methylleucine, MeIle, 
       MeVal, N-methylthreonine, N-methylalanine, allo-MeIle, 
       allo-N-methylthreonine, N-ethylvaline, N-ethylisoleucine, N-ethylthreonine, 
       N-ethylphenylalanine, N-ethyltyrosine, or N-ethylthreonine(Oacetyl)
       

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa is Val, Leu, N-methylvaline, or N-methylleucine

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is N-methylleucine, gamma-hydroxy-N-methylleucine, or 
       N-methylalanine

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is D-alanine

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa is N-methylleucine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is N-methylleucine

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa is N-methylvaline

<400>  1

Xaa Xaa Xaa Xaa Xaa Xaa Ala Xaa Xaa Xaa Xaa 
1               5                   10      


<210>  2
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Cyclosporin formula 2


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is N-methyl-(4R)-but-2E-en-1-yl-4-methyl(L)threonine or 
       6,7,dihydro-N-methyl-(4R)-but-2E-en-1-yl-4-methyl(L)threonine

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is alpha-aminobutyric acid, norvaline, Val, or Thr

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is sarcosine, (D)-N-methylserine, (D)-N-methylalanine, or 
       (D)-N-methylserine(Oacyl)

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is (N-R)aa where aa={Val, Ile, Thr, Phe, Tyr, Thr(OAc), Thr(OG1),
       Phe(G2), PheCH2(G3), or Tyr(OG3)} with R={alkyl>CH3}; G1={phenyl-COOH, 
       phenyl-COOMe, or phenyl-COOEt}; G2={CH2COOH, CH2COOMe(Et)4, CH2PO(OMe)2 
       or CH2PO(OH)2}; G3={PO(OH)2, PO(OCH2CH==CH2)2, CH2COOH, CH2COOMe, or CH2COOEt}

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is N-methylleucine

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is (D)-alanine

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa is N-methylleucine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is N-methylleucine

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa is N-methylvaline

<400>  2

Xaa Xaa Xaa Xaa Val Xaa Ala Xaa Xaa Xaa Xaa 
1               5                   10      


<210>  3
<211>  11
<212>  PRT
<213>  Tolypocladium inflatum


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is N-methyl-(4R)-but-2(E)-en-1-yl-4-methyl-(L)-threonine

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is alpha-aminobutyric acid

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is sarcosine

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is N-methylleucine

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is N-methylleucine

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is (D)-alanine

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa is N-methylleucine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is N-methylleucine

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa is N-methylvaline

<400>  3

Xaa Xaa Xaa Xaa Val Xaa Ala Xaa Xaa Xaa Xaa 
1               5                   10      


<210>  4
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclophilin substrate

<400>  4

Ala Ala Pro Phe 
1               


<210>  5
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  [D-MeAla]3-[EtVal]4-CsA


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Xaa is N-methyl-(4R)-4-but-2E-en-1-yl-4-methyl-(L)threonine

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa is alpha-aminobutyric acid

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa is (D)-N-methylalanine

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa is N-ethylvaline

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa is N-methylleucine

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa is (D)-alanine

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Xaa is N-methylleucine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa is N-methylleucine

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  Xaa is N-methylvaline

<400>  5

Xaa Xaa Xaa Xaa Val Xaa Ala Xaa Xaa Xaa Xaa 
1               5                   10      


